{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02291770",
      "OrgStudyIdInfo": {
        "OrgStudyId": "No.GRDEC 2014210H"
      },
      "Organization": {
        "OrgFullName": "Guangdong Provincial People's Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells",
      "OfficialTitle": "Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China.",
      "Acronym": "MSC-cGvHD"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2014",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "November 2015",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2019",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 5, 2014",
      "StudyFirstSubmitQCDate": "November 11, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 14, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 11, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 14, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Guangdong Provincial People's Hospital",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Sun Yat-sen University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Nanfang Hospital of Southern Medical University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Guangzhou General Hospital of Guangzhou Military Command",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Third Affiliated Hospital, Sun Yat-Sen University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Guangzhou First People's Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Academy Military Medical Science, China",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Chronic Graft-versus-Host Disease (cGvHD) is a potentially lethal disorder. A variety of second line immunosuppressive agents have been investigated but no optimal treatment has emerged. There is therefore a need for novel treatment strategies. Mesenchymal stromal cells (MSC) exhibit immunomodulatory properties and a recent pilot study suggests a response rate of 70% in steroid- refractory patients. In the present randomized study the efficacy and safety of MSC treatment will be further studied in patients with cGvHD."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Chronic Graft-Versus-Host Disease"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Chronic Graft-Versus-Host Disease",
          "Mesenchymal Stromal Cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 3"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "130",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stem cells (MSC)",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Patients with newly diagnosed cGvHD receive primary treatment plus MSC:\n\nMSC+prednisone+cyclosporine;\nMSC+prednisone+tacrolimus;\nMSC+prednisone+mycophenolate mofetil.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Stromal Cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Patients with newly diagnosed cGvHD receive primary treatment:\n\nPlacebo+prednisone+cyclosporine;\nPlacebo+prednisone+tacrolimus;\nPlacebo+prednisone+mycophenolate mofetil."
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal Stromal Cells",
            "InterventionDescription": "Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2Ã—1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stem cells (MSC)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "MSC"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Proportion of patients responding to treatment of cGvHD with MSC",
            "PrimaryOutcomeTimeFrame": "90 days"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Overall survival",
            "SecondaryOutcomeTimeFrame": "2 year"
          },
          {
            "SecondaryOutcomeMeasure": "Progression-free survival",
            "SecondaryOutcomeTimeFrame": "2 year"
          },
          {
            "SecondaryOutcomeMeasure": "Time without systemic immunosuppression",
            "SecondaryOutcomeTimeFrame": "2 year"
          },
          {
            "SecondaryOutcomeMeasure": "Cumulative incidents of non-relapse mortality",
            "SecondaryOutcomeTimeFrame": "2 year"
          },
          {
            "SecondaryOutcomeMeasure": "Adverse events",
            "SecondaryOutcomeTimeFrame": "2 year"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Quality of life",
            "OtherOutcomeTimeFrame": "2 year"
          },
          {
            "OtherOutcomeMeasure": "Immune reconstitution including monitoring of absolute T-cell subsets, B-cells, NK-cells as well as biomarkers of cGvHD",
            "OtherOutcomeTimeFrame": "2 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nNewly diagnosed cGvHD\nInformed consent obtained from patient and donor.\nAny patient who has undergone allogeneic stem cell transplantation with c GvHD.\nHave not received additional agent for cGVHD within 3 months.\nExpected life is more than 90 days.\nAdequate pulmonary function with no evidence of chronic obstructive or severe restrictive pulmonary disease.\nAdequate cardiac function with no evidence of uncontrolled high blood pressure,congestive heart failure, angina pectoris, acute myocardial infarction within 6 months prior to the process.\n\nExclusion Criteria:\n\nInvasive fungal disease.\nActive cytomegalovirus (CMV)/Epstein-Barr virus(EBV)/varicella disease).\nPatient is with a history of hypersensitivity to bovine products.\nRelapsed malignancy.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "14 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Xin Du, Prof.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86 02083827812-62122",
            "CentralContactEMail": "miyadu@hotmail.com"
          },
          {
            "CentralContactName": "Jianyu Weng, Prof.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86 02083827812-62122",
            "CentralContactEMail": "wengjianyu1969@163.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Xin Du, Prof.",
            "OverallOfficialAffiliation": "Guangdong Provincial People's Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Xin Du",
            "LocationStatus": "Recruiting",
            "LocationCity": "Guangzhou",
            "LocationState": "Guangdong",
            "LocationZip": "510080",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Xin Du, Prof.",
                  "LocationContactRole": "Contact",
                  "LocationContactEMail": "miaydu@hotmail.com"
                },
                {
                  "LocationContactName": "Peilong Lai, Dr.",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+86 02083827812-62121",
                  "LocationContactEMail": "lai_peilong@163.com"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "23070118",
            "ReferenceType": "background",
            "ReferenceCitation": "Weng J, He C, Lai P, Luo C, Guo R, Wu S, Geng S, Xiangpeng A, Liu X, Du X. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther. 2012 Dec;20(12):2347-54. doi: 10.1038/mt.2012.208. Epub 2012 Oct 16."
          },
          {
            "ReferencePMID": "20818445",
            "ReferenceType": "background",
            "ReferenceCitation": "Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, Deng CX, Liao PJ, Xiang AP. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010 Dec;45(12):1732-40. doi: 10.1038/bmt.2010.195. Epub 2010 Sep 6."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1303",
            "ConditionBrowseLeafName": "Chronic Graft Versus Host Disease",
            "ConditionBrowseLeafAsFound": "Chronic Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M13273",
            "InterventionBrowseLeafName": "Prednisone",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M11280",
            "InterventionBrowseLeafName": "Mycophenolic Acid",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18113",
            "InterventionBrowseLeafName": "Cyclosporine",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M5882",
            "InterventionBrowseLeafName": "Cyclosporins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18102",
            "InterventionBrowseLeafName": "Tacrolimus",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Infl",
            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          }
        ]
      }
    }
  }
}